Abingworth, a UK-based life sciences investor backed by Carlyle, is raising up to $1.5bn for clinical trials and royalty partnerships with pharmaceutical companies. Recent collaborations with Gilead Sciences and Teva demonstrate the fund’s focus on funding late-stage trials for promising drugs. Abingworth’s successful track record in phase-three trials, coupled with the current demand for new medicines, positions the fund as an attractive option for pharma companies seeking to maximize drug development opportunities.
Full Article
Loading PerspectiveSplit analysis...
